News und Analysen

Shares of Humana (NYSE: HUM) are down 11.7% on Thursday after the health insurance giant announced weaker-than-expected quarterly results and light profit guidance for the coming year.

Humana's

Shares of ResMed (NYSE: RMD) were jumping 7% as of 11:25 a.m. ET on Thursday after rising as much as 10.6% earlier in the morning. The solid gain came after the medical device maker announced

Those who put money in Vertex Pharmaceuticals (NASDAQ: VRTX) 10 years ago are sitting pretty right now. The company has easily outpaced the market over this period.

However, a lot has changed for

Those who put money in Vertex Pharmaceuticals (NASDAQ: VRTX) 10 years ago are sitting pretty right now. The company has easily outpaced the market over this period.

However, a lot has changed for

Those who put money in Vertex Pharmaceuticals (NASDAQ: VRTX) 10 years ago are sitting pretty right now. The company has easily outpaced the market over this period.

However, a lot has changed for

Sarepta Therapeutics (NASDAQ: SRPT) and Vertex Pharmaceuticals (NASDAQ: VRTX) have a lot in common: Both operate in the tricky biotech industry, and both seek to develop treatments primarily for

Building a balanced portfolio requires careful planning and execution. You need to think about your long-term objectives for growth and income, as well as tax implications, when you need to adjust

Building a balanced portfolio requires careful planning and execution. You need to think about your long-term objectives for growth and income, as well as tax implications, when you need to adjust

As you build your portfolio through the years, you may find that you gravitate toward stocks across an assortment of sectors, with a range of risk profiles, growth stories, and businesses

Image source: The Motley Fool.

Abbott Laboratories (NYSE: ABT)Q4 2023 Earnings CallJan 24, 2024, 9:00 a.m. ET

Operator

Continue reading

Source Fool.com

It finally happened. About 10 years after being created, gene-editing specialist CRISPR Therapeutics (NASDAQ: CRSP) earned approval for its first therapy late last year. The treatment in question is

It finally happened. About 10 years after being created, gene-editing specialist CRISPR Therapeutics (NASDAQ: CRSP) earned approval for its first therapy late last year. The treatment in question is

It finally happened. About 10 years after being created, gene-editing specialist CRISPR Therapeutics (NASDAQ: CRSP) earned approval for its first therapy late last year. The treatment in question is

I can sum up Pfizer's (NYSE: PFE) stock performance over the last couple of years in one word (and only three letters): ugh. Shares of the big drugmaker have plunged more than 50% since the high set

I can sum up Pfizer's (NYSE: PFE) stock performance over the last couple of years in one word (and only three letters): ugh. Shares of the big drugmaker have plunged more than 50% since the high set

Pfizer (NYSE: PFE) ended 2022 with a bang, delivering its highest level of revenue ever -- $100 billion -- thanks to its coronavirus vaccine and treatment. But the drop in demand for those products

Pfizer (NYSE: PFE) ended 2022 with a bang, delivering its highest level of revenue ever -- $100 billion -- thanks to its coronavirus vaccine and treatment. But the drop in demand for those products

Many stocks performed well last year, but Medtronic (NYSE: MDT) wasn't one of them. The medical device giant failed to keep pace with broader equities, partly because it was still dealing with

Shares of Coherus BioSciences (NASDAQ: CHRS) were sinking 8.6% lower as of 11:14 a.m. ET on Tuesday. The decline followed a nice pop for the stock on Monday after Coherus announced it was selling

With CRISPR Therapeutics (NASDAQ: CRSP) in the news thanks to its successful work in developing cutting-edge gene therapies, it's easy to assume that everything in the business is going swimmingly

With CRISPR Therapeutics (NASDAQ: CRSP) in the news thanks to its successful work in developing cutting-edge gene therapies, it's easy to assume that everything in the business is going swimmingly

With CRISPR Therapeutics (NASDAQ: CRSP) in the news thanks to its successful work in developing cutting-edge gene therapies, it's easy to assume that everything in the business is going swimmingly

Novavax (NASDAQ: NVAX) soared more than 2,700% early in the pandemic as investors bet on its ability to bring a coronavirus vaccine to market. The company followed through on that -- but not as

On Jan. 8, pharmaceutical giant Merck (NYSE: MRK) moved to acquire biotech Harpoon Therapeutics, (NASDAQ: HARP) for $680 million in cash. The point of the acquisition, which should close in the